International Guideline Harmonization Group
  • Home
  • About IGHG
    • Members
      • Core group
      • Guideline panels
        • Breast cancer
        • Cardiomyopathy
        • Premature ovarian insufficiency
        • Male gonadotoxicity
        • Thyroid cancer
        • Ototoxicty
        • Obstetric care
        • Central nervous system neoplasms
        • Fatigue, mental health and psychosocial problems
        • Fertility preservation
        • Hypothalamic-pituitary dysfunction
        • Coronary artery disease
        • Metabolic syndrome
        • Pulmonary dysfunction
        • Bone mineral density
        • Hepatic toxicity
        • Nephrotoxicity
        • Neurocognitive problems
        • Colorectal cancer
        • Splenic dysfunction
        • Dexrazoxane cardioprotection
        • Growth hormone treatment
        • COVID-19 Statement
        • Thyroid dysfunction
    • Collaborators
    • Funding sources
    • Methods
      • Process
      • Grading system
      • Topic selection
      • Publication
      • Handbook
  • Guidelines
    • Topics
      • Breast cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Cardiomyopathy
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Premature ovarian insufficiency
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Male gonadotoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Thyroid cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Ototoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Obstetric care
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Central nervous system neoplasms
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fatigue
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Psychosocial problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Mental health problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Coronary artery disease
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fertility preservation
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publications
        • Guideline panel
      • Bone mineral density
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hepatic toxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hypothalamic-pituitary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Metabolic syndrome
        • Guideline panel
      • Nephrotoxicity
        • Guideline panel
      • Colorectal cancer
        • Guideline panel
      • Neurocognitive problems
        • Guideline panel
      • Pulmonary dysfunction
        • Guideline panel
      • Splenic dysfunction
        • Guideline panel
      • Dexrazoxane cardioprotection
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Growth hormone treatment
      • Thyroid dysfunction
        • Guideline panel
      • COVID-19 Statement
  • Patient education
  • News
  • Meetings
  • Contact

Male gonadotoxicity

Home Guidelines Topics Male gonadotoxicity Conclusions of evidence

  • Topics
    • Breast cancer
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Cardiomyopathy
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Premature ovarian insufficiency
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Male gonadotoxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Thyroid cancer
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Ototoxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Obstetric care
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Central nervous system neoplasms
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Fatigue
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Psychosocial problems
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Mental health problems
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Coronary artery disease
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Fertility preservation
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publications
      • Guideline panel
    • Bone mineral density
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Hepatic toxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Hypothalamic-pituitary dysfunction
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Metabolic syndrome
      • Guideline panel
    • Nephrotoxicity
      • Guideline panel
    • Colorectal cancer
      • Guideline panel
    • Neurocognitive problems
      • Guideline panel
    • Pulmonary dysfunction
      • Guideline panel
    • Splenic dysfunction
      • Guideline panel
    • Dexrazoxane cardioprotection
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Growth hormone treatment
    • Thyroid dysfunction
      • Guideline panel
    • COVID-19 Statement

Conclusions of evidence

The conclusions and levels of evidence of gonadotoxicity surveillance for male childhood, adolescent and young adult cancer survivors are presented in the following documents:

Conclusions and levels of evidence male gonadotoxicity surveillance

Conclusions of evidence tables from systematic search male gonadotoxicity surveillance

Summary of evidence from the supplemental literature search male gonadotoxicity surveillance

See The Lancet Oncology for the publication.

  • Contact
  • Disclaimer

© International Guideline Harmonization Group